Shariful Islam Sheikh Mohammed, Lechner Andreas, Ferrari Uta, Laxy Michael, Seissler Jochen, Brown Jonathan, Niessen Louis W, Holle Rolf
NCD Unit, International Center for Diarrhoeal Diseases Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh.
Center for International Health (CIH), Ludwig-Maximilians-Universität (LMU), Munich, Germany.
BMJ Glob Health. 2017 Jan 3;2(1):e000033. doi: 10.1136/bmjgh-2016-000033. eCollection 2017.
Diabetes imposes a huge social and economic impact on nations. However, information on the costs of treating and managing diabetes in developing countries is limited. The aim of this study was to estimate healthcare use and expenditure for diabetes in Bangladesh.
We conducted a matched case-control study between January and July 2014 among 591 adults with diagnosed diabetes mellitus (DMs) and 591 age-matched, sex-matched and residence-matched persons without diabetes mellitus (non-DMs). We recruited DMs from consecutive patients and non-DMs from accompanying persons in the Bangladesh Institute of Health Science (BIHS) hospital in Dhaka, Bangladesh. We estimated the impact of diabetes on healthcare use and expenditure by calculating ratios and differences between DMs and non-DMs for all expenses related to healthcare use and tested for statistical difference using Student's t-tests.
DMs had two times more days of inpatient treatment, 1.3 times more outpatient visits, and 9.7 times more medications than non-DMs (all p<0.005). The total annual per capita expenditure on medical care was 6.1 times higher for DMs than non-DMs (US$635 vs US$104, respectively). Among DMs, 9.8% reported not taking any antidiabetic medications, 46.4% took metformin, 38.7% sulfonylurea, 40.8% insulin, 38.7% any antihypertensive medication, and 14.2% took anti-lipids over the preceding 3 months.
Diabetes significantly increases healthcare use and expenditure and is likely to impose a huge economic burden on the healthcare systems in Bangladesh. The study highlights the importance of prevention and optimum management of diabetes in Bangladesh and other developing countries, to gain a strong economic incentive through implementing multisectoral approach and cost-effective prevention strategies.
糖尿病给各国带来了巨大的社会和经济影响。然而,关于发展中国家糖尿病治疗和管理成本的信息有限。本研究的目的是估计孟加拉国糖尿病的医疗保健使用情况和支出。
2014年1月至7月,我们对591名确诊糖尿病(DMs)的成年人与591名年龄、性别和居住地匹配的非糖尿病患者(非DMs)进行了配对病例对照研究。我们从达卡孟加拉国健康科学研究所(BIHS)医院的连续患者中招募DMs,从陪同人员中招募非DMs。我们通过计算DMs和非DMs在所有与医疗保健使用相关费用上的比率和差异,估计糖尿病对医疗保健使用和支出的影响,并使用学生t检验进行统计学差异检验。
DMs的住院治疗天数是非DMs的两倍,门诊就诊次数是非DMs的1.3倍,药物使用量是非DMs的9.7倍(所有p<0.005)。DMs的人均年度医疗总支出是非DMs的6.1倍(分别为635美元和104美元)。在DMs中,9.8%的人报告在过去3个月内未服用任何抗糖尿病药物,46.4%的人服用二甲双胍,38.7%的人服用磺脲类药物,40.8%的人服用胰岛素,38.7%的人服用任何抗高血压药物,14.2%的人服用降脂药物。
糖尿病显著增加了医疗保健的使用和支出,可能给孟加拉国的医疗保健系统带来巨大经济负担。该研究强调了在孟加拉国和其他发展中国家预防和优化糖尿病管理的重要性,通过实施多部门方法和具有成本效益的预防策略来获得强大的经济激励。